Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cyclooxygenase-2 inhibitors.

Christopher J Hawkey¹, Paul J Fortun

¹Wolfson Digestive Diseases Centre, University of Nottingham, University Hospital, UK. cj.hawley@nottingham.ac.uk

Current Opinion in Gastroenterology

|October 13, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.

Health technology assessment (Winchester, England)·2024

Same author

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.

Lancet (London, England)·2022

Same author

Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.

Trials·2022

Same author

Recruitment to a large scale randomised controlled clinical trial in primary care: the Helicobacter Eradication Aspirin Trial (HEAT).

Trials·2022

Same author

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.

Lancet (London, England)·2020

Same author

Living with Crohn's disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study).

BMJ open·2017

Selective cyclooxygenase-2 inhibitors offer pain relief with fewer gastrointestinal issues. However, some, like rofecoxib, may increase heart attack risk, necessitating careful patient selection.

Area of Science:

Pharmacology
Gastroenterology
Cardiology

Background:

Selective cyclooxygenase-2 (COX-2) inhibitors provide an alternative to nonselective NSAIDs for pain and inflammation.
These agents offer improved gastrointestinal safety profiles compared to traditional NSAIDs.

Purpose of the Study:

To review current data on selective COX-2 inhibitors.
To focus on recent findings concerning cardiovascular risks associated with their use.

Main Methods:

Literature review of studies on selective COX-2 inhibitors.
Analysis of clinical trial data and regulatory agency conclusions.

Main Results:

Selective COX-2 inhibitors are effective for pain and inflammation with fewer GI ulcers.

Related Experiment Videos

Some COX-2 inhibitors, notably rofecoxib, have been linked to increased myocardial infarction risk.

Data on celecoxib's cardiovascular risk remain inconclusive; rofecoxib was withdrawn from the market.

Conclusions:

Rofecoxib, and potentially other selective COX-2 inhibitors, may increase myocardial infarction risk.
Cardiovascular risk associated with selective COX-2 inhibitors requires careful consideration, especially in high-risk patients.
Further research is needed to fully elucidate the cardiovascular effects of selective COX-2 inhibitors and nonselective NSAIDs.